-
Disease-modifying therapies in multiple sclerosis: A focused review of rituximab
- Basic & Clinical Pharmacology & Toxicology
- DOI: 10.1111/bcpt.13932
Peter Alping
Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC)
Xcitations -
Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
- Multiple Sclerosis
- DOI: 10.1177/13524585231161492
Katharina Fink, Agnes Gorczyca, Peter Alping, Simon Englund, Susan Farmand, Annette M. Langer-Gould, Fredrik Piehl, Kyla McKay, Thomas Frisell, and Neda Razaz
Creative Commons Attribution 4.0 International License (CC-BY)
2citations
-
Pharmacoepidemiological Studies of Rituximab and Other Recent Therapies in Multiple Sclerosis
- Thesis
- Karolinska Institutet
- Sweden
Peter Alping
Creative Commons Attribution 4.0 International License (CC-BY)
Xcitations
-
Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Non-induction Therapies for Multiple Sclerosis
- Neurology
- DOI: 10.1212/wnl.0000000000011545
Peter Alping, Joachim Burman, Jan Lycke, Thomas Frisell, and Fredrik Piehl
Creative Commons Attribution 4.0 International License (CC-BY)
9citations
-
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
- Annals of Neurology
- DOI: 10.1002/ana.25701
Peter Alping, Johan Askling, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Magnus Vrethem, Tomas Olsson, Fredrik Piehl, and Thomas Frisell
Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC)
68citations
-
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
- JAMA Neurology
- DOI: 10.1001/jamaneurol.2019.3365
Gustavo Luna, Peter Alping, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Magnus Vrethem, Tomas Olsson, Fredrik Piehl, and Thomas Frisell
Copyright 2019 American Medical Association. All Rights Reserved.
312citations -
Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations
- Epidemiology
- DOI: 10.1097/ede.0000000000000948
Peter Alping, Fredrik Piehl, Annette Langer-Gould, Thomas Frisell, and COMBAT-MS Study Group
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC-BY-NC-ND)
41citations
-
Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
- Neurology
- DOI: 10.1212/wnl.0000000000003331
Jonatan Salzer, Rasmus Svenningsson, Peter Alping, Lenka Novakova, Anna Björck, Katharina Fink, Protik Islam-Jakobsson, Clas Malmeström, Markus Axelsson, Mattias Vågberg, Peter Sundström, Jan Lycke, Fredrik Piehl, and Anders Svenningsson
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC-BY-NC-ND)
262citations -
Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
- Annals of Neurology
- DOI: 10.1002/ana.24651
Peter Alping, Thomas Frisell, Lenka Novakova, Protik Islam-Jakobsson, Jonatan Salzer, Anna Björck, Markus Axelsson, Clas Malmeström, Katharina Fink, Jan Lycke, Anders Svenningsson, and Fredrik Piehl
Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC)
181citations